Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05986682 · OUTCOME

Ophthalmology: Number of Ocular Symptoms Reported

Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple Myeloma · Source last updated 2025-02-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_UNITS
Unit
Ocular Symptoms
Interval / dispersion
Not reported
Time frame
Between baseline and earliest of end of BLENREP treatment, death, lost to contact or end of study timeframe, up to 40 months.

What was measured

Study procedures included recording ocular symptoms reported by patients documented in the clinic notes. These were categorized into blurry vision, dry eyes, photophobia and other symptoms (including foreign-body sensation, "grittiness", "itch/scratchiness", irritation, and tearing). This Data table reports the total number of Ocular Symptoms reported by patients, along with counts and percentage by type of symptom.

Analysis population: The 30 patients in the study reported specific symptoms a total of 192 times at clinic visits. The analysis population is the 192 symptoms reported.

Groups in this outcome

Multiple Myeloma/Blenrep Participants

Participants with relapsed and/or refractory multiple myeloma who were treated with Belantamab Mafodotin - blmf (BLENREP) in the DCI Oncology outpatient clinics between August 5, 2020 and November 7, 2023

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Multiple Myeloma/Blenrep Participants30

Analysis denominator · Ocular Symptoms

GroupSource count
Multiple Myeloma/Blenrep Participants192

Reported measurements

Number of Ocular Symptoms reported
Values in Ocular Symptoms · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Multiple Myeloma/Blenrep Participants192Not reportedNot reportedNot reportedNot reported
Blurry Vision
Values in Ocular Symptoms · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Multiple Myeloma/Blenrep Participants102Not reportedNot reportedNot reportedNot reported
Dry Eyes
Values in Ocular Symptoms · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Multiple Myeloma/Blenrep Participants32Not reportedNot reportedNot reportedNot reported
Photophobia
Values in Ocular Symptoms · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Multiple Myeloma/Blenrep Participants26Not reportedNot reportedNot reportedNot reported
Other
Values in Ocular Symptoms · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Multiple Myeloma/Blenrep Participants32Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        192
    title
    Number of Ocular Symptoms reported
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        102
    title
    Blurry Vision
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        32
    title
    Dry Eyes
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        26
    title
    Photophobia
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        32
    title
    Other
denom Units Selected
Ocular Symptoms
denoms
  1. counts
    1. group Id
      OG000
      value
      30
    units
    Participants
  2. counts
    1. group Id
      OG000
      value
      192
    units
    Ocular Symptoms
description
Study procedures included recording ocular symptoms reported by patients documented in the clinic notes. These were categorized into blurry vision, dry eyes, photophobia and other symptoms (including foreign-body sensation, "grittiness", "itch/scratchiness", irritation, and tearing). This Data table reports the total number of Ocular Symptoms reported by patients, along with counts and percentage by type of symptom.
groups
  1. description
    Participants with relapsed and/or refractory multiple myeloma who were treated with Belantamab Mafodotin - blmf (BLENREP) in the DCI Oncology outpatient clinics between August 5, 2020 and November 7, 2023
    id
    OG000
    title
    Multiple Myeloma/Blenrep Participants
param Type
COUNT_OF_UNITS
population Description
The 30 patients in the study reported specific symptoms a total of 192 times at clinic visits. The analysis population is the 192 symptoms reported.
reporting Status
POSTED
time Frame
Between baseline and earliest of end of BLENREP treatment, death, lost to contact or end of study timeframe, up to 40 months.
title
Ophthalmology: Number of Ocular Symptoms Reported
type
POST_HOC
type Units Analyzed
Ocular Symptoms
unit Of Measure
Ocular Symptoms

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice